Introduction {#H1-1-ZOI200041}
============

Suicide researchers and prevention specialists use the phrase *means matter* to highlight that the mechanism used strongly influences a suicidal act's lethality.^[@zoi200041r1]^ Through this line of research and practice, means restriction has become a public health focus for population-level suicide prevention.^[@zoi200041r2]^ Analyses of means, however, usually lump almost all drug overdoses into a single category.^[@zoi200041r2],[@zoi200041r3],[@zoi200041r4],[@zoi200041r5],[@zoi200041r6],[@zoi200041r7]^ The partial exception is alcohol; a study of fatal and hospital-admitted cases^[@zoi200041r8]^ estimated that people were 5.1 times more likely to attempt suicide when consuming alcohol than when sober. Another small but robust study^[@zoi200041r9]^ estimated that people were 9.6 times more likely to attempt a medically treated suicide during hours when they were intoxicated. Even these studies did not assess how alcohol involvement affected lethality. A few studies on suicide prevention by means focused on restricting access to specific, easily accessible toxins,^[@zoi200041r10]^ such as pesticides, barbiturates, paracetamol (acetaminophen), or antidepressants. Evaluations found that restricting access to these lethal means through prescription practices and sales regulation was associated with declining suicide rates.^[@zoi200041r10],[@zoi200041r11],[@zoi200041r12]^ Thus, drug suicide prevention efforts will benefit from a systematic investigation of suicide lethality by drug class that assesses the separate and interactive risks of varied drugs.

This study examined the association of drug classes consumed with the lethality of intentionally self-inflicted drug overdoses. We estimated what proportion of people who died of suicidal acts involving specific drugs may have survived their overdose if their drug mix had omitted a given drug class. For example, we analyzed what portion of completed suicides that involved opioids might not have been fatal if opioids were not involved.

Methods {#H1-2-ZOI200041}
=======

This cross-sectional analysis combined mortality and hospital data. Its centerpiece is a tabular and regression analysis of hospital data we previously purchased for unrelated research.^[@zoi200041r13]^ We used mortality data matched by state and year from deidentified, restricted-access Multiple Cause of Death (MCOD) data sets^[@zoi200041r14]^ that recorded the state where the individual died. We restricted analyses to individuals 6 years and older because determining suicidal intent in younger children is often difficult. Most medical examiners do not classify a child's death as a suicide if the child is younger than 10 years^[@zoi200041r15]^; however, suicide cases have been identified in children aged 5 to 9 years.^[@zoi200041r16]^ This secondary analysis of deidentified data was exempted by the institutional review board of the Pacific Institute for Research and Evaluation, and the need for informed consent was waived. We followed the reporting requirements of the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](https://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

We had censuses of deidentified hospital inpatient and emergency department (ED) live discharges from January 1, 2011, through December 31, 2012, from Arizona, Iowa, Nebraska, and Utah for 2012 only; California for 2011 only; and Florida, Kentucky, New Jersey, New York, North Carolina, and Rhode Island for both years. These states accounted for 37% of US residents, 34% of total suicides,^[@zoi200041r17]^ and 39% of drug poisoning suicides in 2012.^[@zoi200041r18]^

To assess the consistency of the 11 states with the nation, we compared their tabular findings vs 2012 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) and Nationwide Emergency Department Sample (NEDS) tables. To ensure that our findings were current, we compared them with 2016 NIS and NEDS tables (the most recent).

Radically different sampling strategies and the absence of state identifiers in HCUP national samples preclude regressions on pooled MCOD, NIS, and NEDS data. The HCUP NIS builds on a 20% sample of discharges from every community hospital in 46 states plus Washington, DC. The HCUP NEDS 2016 sampled discharges from 953 hospitals in 36 states plus Washington, DC; the HCUP NEDS 2012 sampled discharges from 950 hospitals in 30 states. Neither NIS nor NEDS reveals a case's state of origin. It would be impossible to calculate standard errors (SEs) accurately in a pooled data set regression.

We largely restricted our analysis to deaths and live discharges in which drug poisoning was the mechanism of injury and intent was purposefully self-inflicted or, except in sensitivity analysis, undetermined (hereafter collectively labeled *suicidal*). *International Classification of Diseases (ICD)*intent codes do not differentiate suicidal from nonsuicidal self-inflicted intentional injury. Including drug poisonings of undetermined intent was a conservative correction for documented differential undercounting of drug poisoning suicides across states.^[@zoi200041r19]^ The opioid epidemic is severely stressing underresourced emergency health care and medicolegal death investigation systems across the nation. Drug poisoning suicides are especially difficult for death certifiers to ascertain relative to suicides by more behaviorally and forensically overt methods, such as gunshot and hanging.^[@zoi200041r20],[@zoi200041r21]^ *Undetermined* is the manner-of-death category most susceptible to obscuring these suicides.^[@zoi200041r22],[@zoi200041r23]^

We used diagnosis data to determine what drugs, if any, were present in each hospital-treated or fatal poisoning. Presence of alcohol and other drugs was determined using *International Classification of Diseases, Ninth Revision, Clinical Modification* (*ICD-9-CM*) for 2011-2012 hospital data, *International Statistical Classification of Diseases, Tenth Revision, Clinical Modification* (*ICD-10-CM*) for 2016 hospital data, and *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (*ICD-10*) for deaths. We identified drug poisonings of suicidal or undetermined intent by any listed diagnosis/intent code in *ICD-10* or external cause code in *ICD-9-CM*. Except in sensitivity analysis, we then excluded cases that also included another suicide mechanism (eg, fall). We classified the drugs involved into the following categories: 4-aminophenol derivative (eg, acetaminophen), alcohol, antiallergic or antiemetic (a single *ICD* code), antidepressant, antipsychotic (ie, tranquilizers other than benzodiazepines), barbiturate, benzodiazepine, cocaine, hallucinogen, opiate, other nonsteroidal anti-inflammatory drug (eg, ibuprofen), muscle relaxant, psychostimulant, salicylate (eg, aspirin), other specified drug, and unknown drug. Because testing only detects components of combination drugs such as acetaminophen and hydrocodone bitartrate, acetaminophen and oxycodone hydrochloride, or cough medicine with codeine, these drugs were counted both as an opioid and as 1 or more other drug classes. The 2016 analysis differentiated additional drug classes identifiable only in *ICD-10*. eTable 1 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} lists the codes included in each drug class. A maximum of 8 classes were involved in 1 case. Data management and descriptive statistics were conducted with SAS, version 9.4 (SAS Institute Inc) and RStudio, version 1.2.5033 (RStudio Inc).

Drugs involved in suicide acts were not always tested or identifiable. Fewer than 10% of nonfatal poisonings but almost 45% of fatal poisonings included unknown drugs. If the record identified any drugs, we ignored the unknown drugs. For fatalities with all drugs unknown, we used a published regression method^[@zoi200041r24]^ to infer the presence of frequently involved drug classes, that is, opioids, benzodiazepines, and stimulants (with probabilities \>0.33 counted as present). We followed a similar strategy for nonfatal cases but could only use victim sex, age group, and rurality as explanators.

We tabulated the data. By time period, we computed the percentage of cases that were fatal (ie, the case fatality rate) and the risk of suicide due to drug poisoning involving each drug class relative to drug poisonings that did not involve that class (ie, the incidence rate ratio or the risk ratio).

Statistical Analysis {#H2-1-ZOI200041}
--------------------

Data were analyzed from June 2019 to January 2020. Our 2011-2012 state fatality and hospital data were censuses suitable for regression analysis after pooling. Using Stata, version 15.0 (StataCorp LLC), we ran a series of logistic regressions on them. The regressions estimated the odds that a poisoning suicidal act was fatal, with fatal cases equal to 1 and nonfatal cases equal to 0.

Covariates included victim age group (detailed in [Table 1](#zoi200041t1){ref-type="table"}) by sex, 3-category urbanicity (large metropolitan/fringe, medium/small metropolitan, and micropolitan/noncore), and state. The HCUP data include urbanicity; we generated comparable categories from state and county information in the MCOD. The ED data offered no other demographic characteristics.

###### Case Counts of Suicidal Drug Poisoning Overdoses by Characteristics and Year[^a^](#zoi200041t1n1){ref-type="table-fn"}

  Characteristic                                         2011-2012 Events in 11 States   2012 National Events   2016 National Events                                                                            
  ------------------------------------------------------ ------------------------------- ---------------------- ---------------------- ------------- -------------- -------------- ------------- -------------- --------------
  Male                                                   2696                            50 439                 52 452                 5190          99 115 (538)   85 095 (501)   5660          59 618 (419)   52 970 (405)
  Age, y                                                                                                                                                                                                        
  6-14                                                   9                               2460                   6105                   12            10 552 (223)   4765 (153)     26            11 409 (222)   4240 (143)
  15-20                                                  114                             13 839                 25 098                 225           45 657 (429)   24 325 (328)   274           39 757 (375)   20 160 (294)
  21-25                                                  249                             12 000                 16 364                 486           31 338 (368)   20 470 (304)   571           20 787 (290)   14 885 (258)
  26-30                                                  305                             11 389                 13 480                 698           26 261 (341)   19 475 (297)   783           17 046 (266)   13 090 (244)
  31-39                                                  668                             19 539                 19 145                 1431          36 508 (393)   38 495 (396)   1687          23 989 (266)   23 225 (311)
  40-49                                                  1287                            26 345                 19 931                 2446          36 145 (392)   42 270 (410)   2207          20 582 (290)   24 955 (320)
  50-59                                                  1445                            21 556                 13 615                 2746          23 900 (324)   36 440 (387)   2726          15 705 (258)   23 045 (310)
  ≥60                                                    1004                            13 413                 6675                   1649          11 769 (231)   20 730 (305)   2251          7334 (180)     15 560 (263)
  Undetermined intent                                    1211                            27 954                 50 234                 2952          93 556 (538)   44 055 (417)   3809          31 981 (346)   15 730 (264)
  With comorbidities                                     760                             112 017                73 080                 NA            NA             NA             NA            NA             NA
  Drug classes per case (excluding alcohol), mean (SE)   1.37 (0.01)                     1.38 (0.002)           1.04 (0.002)           1.30 (0.01)   1.06 (0.002)   1.41 (0.004)   1.40 (0.01)   1.21 (0.003)   1.45 (0.01)
  4-Aminophenol derivative                               278                             15715                  9435                   393           16 159 (273)   26 950 (342)   387           14 228 (246)   19 355 (289)
  Alcohol                                                550                             8621                   7535                   1123          11 038 (231)   14 535 (260)   1429          7153 (178)     11 080 (226)
  Antiallergic/antiemetic                                373                             5218                   4238                   602           8461 (207)     10 580 (224)   813           8610 (195)     9225 (208)
  Antidepressant                                         851                             16 567                 10 160                 1615          20 696 (311)   32 445 (370)   1714          21 519 (297)   24 240 (316)
  Antidiabetic                                           55                              2318                   845                    87            1603 (85)      4400 (147)     117           1277 (78)      3670 (134)
  Antiepileptic                                          282                             6802                   4580                   471           8942 (212)     12 145 (239)   688           9665 (206)     13 960 (251)
  Antiparkinsonian                                       81                              2881                   2449                   140           3933 (136)     4775 (153)     123           2117 (99)      3635 (133)
  Barbiturate                                            95                              1146                   307                    150           555 (50)       1865 (96)      157           268 (35)       865 (66)
  Benzodiazepine                                         808                             34 291                 20 372                 1245          39 026 (414)   58 700 (459)   1551          25 283 (316)   33 020 (355)
  Cocaine                                                130                             7010                   2520                   228           4495 (144)     8200 (198)     470           2014 (95)      3585 (132)
  Hallucinogen                                           13                              1917                   2426                   28            4652 (146)     3075 (123)     28            2478 (106)     1990 (99)
  Muscle relaxant                                        3                               2707                   1280                   7             2646 (113)     5505 (164)     219           2077 (99)      3115 (124)
  Opioid                                                 1981                            19 749                 16 148                 3226          35 350 (381)   33 250 (374)   4386          26 196 (319)   21 635 (302)
  Other analgesic                                        5                               380                    426                    7             746 (62)       510 (50)       4             535 (50)       380 (44)
  Other antipsychotic                                    282                             10 818                 6070                   500           11 202 (233)   19 250 (295)   653           11 978 (228)   16 970 (273)
  Other NSAID                                            26                              4796                   7117                   39            13 515 (248)   8680 (204)     36            14 956 (251)   8515 (200)
  Psychostimulant                                        116                             3436                   2996                   218           6138 (171)     7040 (184)     417           5843 (163)     5635 (164)
  Salicylate                                             58                              3237                   1936                   100           3397 (128)     6085 (172)     69            2812 (114)     3830 (136)
  Other named drug class                                 546                             22 435                 15 955                 904           31 055 (366)   40 905 (405)   722           18 357 (276)   21 665 (302)
  Unknown drug only                                      704                             3523                   15 066                 1470          28 001 (353)   9915 (217)     1522          19 115 (279)   6920 (181)

Abbreviations: ED, emergency department; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug.

Unweighted counts are given in eTable 1 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"}. Unless otherwise indicated, data are expressed as number of cases.

Regressions included the presence of comorbidities as a covariate. We searched the record for the 30 Elixhauser comorbid conditions.^[@zoi200041r25]^ Hospitals assiduously code comorbidities, which can affect treatment choices or require maintaining a medication regimen or diet. Conversely, death certifiers only record comorbidities that contributed to the death.^[@zoi200041r26]^ Therefore, we treated comorbidity as an absent-present variable rather than a count.

Three overarching regression models covered all drug classes. Model 1 included binary variables indicating the drug classes involved. Models 2 and 3 were sensitivity analyses that paralleled model 1. Model 2 omitted cases in which none of the drug classes involved were known or inferable. Model 3 omitted cases of undetermined intent. Because exploratory data tabulations suggested youths used different drug mixes than adults, we also ran model 1 separately for those 21 years or older and younger than 21 years.

Additional regressions further probed the lethality of the 9 classes of drugs with at least 100 deaths in the 2011-2012 sample. These regressions (model 4) added a set of interaction terms between the binary indicator variable for the drug class of interest and the indicator variables for the other drug classes. We calculated the increased lethality if a focal drug class was involved in a suicide act in 2 steps.^[@zoi200041r27]^ First, we summed the regression coefficients for the drug class indicator and its interaction terms multiplied by the percentage of a drug class' cases that involved each interaction. Then we exponentiated the sum to generate the adjusted odds ratio. Model 4 provides our best estimates. Model 1 is best for drug classes with too few deaths to calculate model 4 reliably. By including cases with only unknown drugs and cases of undetermined intent, these models should reduce the biases resulting from differential coding in the fatal and nonfatal data.

Model 5 paralleled model 1 but included suicidal acts from all mechanisms, with binary variables indicating the primary mechanism. The findings appear in eTable 2 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"}.

We converted the odds ratios to relative risks (RRs) using a correction formula that derives directly from the definitions of the 2 terms.^[@zoi200041r28]^ That formula is apropos because we have a census of cases. For RRs exceeding 1.00, we computed the fraction of deaths involving the focal drug class that would not have been fatal if no drugs in that class had been present. We calculated this drug-attributable fraction among the exposed by subtracting the base risk of 1.00 from the RR and then dividing by the RR.^[@zoi200041r29],[@zoi200041r30]^

Results {#H1-3-ZOI200041}
=======

A total of 421 466 drug poisoning suicidal acts resulted in 21 594 deaths (46.2% men, 53.8% women, and \<0.01% missing; mean age, 36.4 years). [Table 1](#zoi200041t1){ref-type="table"} and [Table 2](#zoi200041t2){ref-type="table"} as well as eTable 3 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} describe the suicidal acts and drug classes analyzed in the 3 populations: 246 362 events in the 2011-2012 state censuses (including 5081 deaths), 102 946 events (unweighted) in the 2012 national data (including 9693 deaths, with 48 340 nonfatal events and 1211 deaths also in the state censuses), and 73 369 events in the 2016 national data (including 10 525 deaths). In 2016, a nonfatal act treated in the ED involved a mean (SE) of 1.45 (0.01) drug classes; an admitted act, 1.21 (0.003) drug classes; and a fatality, 1.40 (0.004) drug classes, excluding alcohol. Across the 3 measurements, benzodiazepines were involved in 19.6% to 22.5% of the suicidal overdoses ([Table 2](#zoi200041t2){ref-type="table"}). They were the drug class most often involved in nonfatal acts. Among fatalities, opioids (33.3%-47.8% of cases), antidepressants (16.3%-16.7%), and benzodiazepines (12.8%-15.9%) were most often involved.

###### Distribution of Suicidal Acts Between Categories, Distribution of Drugs Involved in Fatal Cases, and Unadjusted RRs of Death by Characteristics and Year

  Characteristic             Suicidal acts, %   RR (95% CI)                                                                     
  -------------------------- ------------------ ------------- ------ ------ ------ ------ ------------------ ------------------ ------------------
  Male                       42.9               42.8          38.7   53.1   53.5   53.8   1.51 (1.43-1.59)   1.60 (1.54)        1.94 (1.87-2.02)
  Age, y                                                                                                                        
  6-14                       3.5                3.5           5.1    0.2    0.1    0.2    0.05 (0.02-0.08)   0.04 (0.02-0.06)   0.05 (0.03-0.07)
  15-20                      15.9               15.9          19.7   2.2    2.3    2.6    0.12 (0.10-0.15)   0.13 (0.11-0.15)   0.11 (0.10-0.13)
  21-25                      11.6               11.8          11.9   4.9    5.0    5.4    0.39 (0.35-0.44)   0.40 (0.37-0.44)   0.44 (0.41-0.48)
  26-30                      10.2               10.5          10.1   6.0    7.2    7.4    0.56 (0.50-0.63)   0.69 (0.63-0.73)   0.74 (0.69-0.79)
  31-39                      16.0               17.3          16.0   13.1   14.8   16.0   0.80 (0.73-0.86)   0.86 (0.81-0.90)   1.04 (0.99-1.09)
  40-49                      19.3               18.3          15.6   25.3   25.2   21.0   1.42 (1.33-1.51)   1.55 (1.48-1.62)   1.49 (1.42-1.56)
  50-59                      14.9               14.3          13.6   28.4   28.3   25.9   2.28 (2.14-2.42)   2.44 (2.33-2.55)   2.31 (2.21-2.41)
  ≥60                        8.6                7.7           8.2    19.8   17.0   21.4   2.63 (2/46-2.81)   2.51 (2.38-2.65)   3.14 (3.01-3.29)
  Undetermined intent        32.2               31.8          16.9   32.2   30.5   36.2   0.66 (0.62-0.70)   0.97 (0.93-1.01)   2.91 (2.80-3.02)
  With comorbidities         85.0               NA            NA     15.0   NA     NA     0.06 (0.05-0.06)   NA                 NA
  4-Aminophenol derivative   11.2               9.9           11.1   5.5    4.1    3.7    0.50 (0.44-0.57)   0.40 (0.36-0.44)   0.32 (0.28-0.35)
  Alcohol                    6.8                6.1           6.4    10.8   11.6   13.6   1.67 (1.53-1.82)   2.09 (1.97-2.22)   2.37 (2.24-2.50)
  Antiallergic/antiemetic    4.0                4.4           6.1    7.3    6.2    7.7    1.91 (1.71-2.11)   1.46 (1.34-1.58)   1.33 (1.24-1.43)
  Antidepressant             11.2               12.4          15.5   16.7   16.7   16.3   1.60 (1.49-1.71)   1.45 (1.38-1.53)   1.10 (1.05-1.16)
  Antidiabetic               1.3                1.4           1.7    1.1    0.9    1.1    0.83 (0.62-1.05)   0.66 (0.53-0.81)   0.69 (0.56-0.82)
  Antiepileptic              4.7                4.9           8.0    5.6    4.9    6.5    1.18 (1.04-1.33)   1.02 (0.92-1.11)   0.84 (0.78-0.90)
  Antiparkinsonian           2.2                2.0           1.9    1.6    1.4    1.2    0.72 (0.57-0.88)   0.73 (0.62-0.86)   0.62 (0.52-0.73)
  Barbiturate                0.6                0.6           0.4    1.9    1.5    1.5    3.01 (2.43-3.60)   2.75 (2.34-3.19)   3.69 (3.14-4.25)
  Benzodiazepine             22.5               21.4          19.6   15.9   12.8   14.7   0.65 (0.60-0.70)   0.53 (0.50-0.56)   0.74 (0.70-0.78)
  Cocaine                    3.9                2.9           2.0    2.6    2.4    4.5    0.64 (0.53-0.76)   0.82 (0.72-0.93)   2.39 (2.18-2.60)
  Hallucinogen               1.8                1.8           1.5    0.3    0.3    0.3    0.14 (0.08-0.23)   0.17 (0.11-0.23)   0.18 (0.12-0.26)
  Muscle relaxant            1.6                1.8           1.8    0.1    0.1    2.1    0.04 (0.00-0.08)   0.04 (0.01-0.07)   1.22 (1.06-1.38)
  Opioid                     15.4               16.1          17.3   39.0   33.3   47.8   3.52 (3.32-3.71)   2.64 (2.53-2.75)   4.55 (4.38-4.73)
  Other analgesic            0.3                0.3           0.3    0.1    0.1    0.0    0.30 (0.06-0.60)   0.26 (0.07-0.48)   0.13 (0.03-0.26)
  Other antipsychotic        7.0                7.0           9.7    5.6    5.2    6.2    0.78 0.69-0.88)    0.74 (0.68-0.81)   0.64 (0.59-0.69)
  Other NSAID                4.8                5.0           7.7    0.5    0.4    0.3    0.10 (0.06-0.14)   0.08 (0.05-0.10)   0.04 (0.03-0.06)
  Psychostimulant            2.7                3.0           3.9    2.3    2.2    4.0    0.86 (0.70-1.01)   0.75 (0.65-0.86)   1.05 (0.95-1.16)
  Salicylate                 2.1                2.2           2.2    1.1    1.0    0.7    0.53 (0.40-0.67)   0.48 (0.39-0.60)   0.30 (0.23-0.38)
  Other named drug class     15.8               16.0          13.4   10.7   9.3    7.5    0.64 (0.59-0.70)   0.54 (0.50-0.57)   0.54 (0.51-0.58)
  Unknown drug only          7.8                8.9           7.9    3.6    15.2   14.5   1.89 (1.74-2.04)   1.87 (1.77-1.98)   1.77 (1.67-1.86)

Abbreviations: NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug; RR, relative risk.

The case fatality rate (eTable 3 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"}) measures lethality. It was higher for males (2.6%-4.8%) than females (1.7%-2.6%) and increased with age group (6-14 years, 0.1%-0.2%; ≥60 years, 4.8%-9.0%). It consistently was highest for opioids (4.5%-9.5%), followed by antidepressants (2.9%-3.6%) and barbiturates (5.8%-12.2%). eTable 4 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} shows the percentage of cases within a given drug class for which that drug class was the only class identified for fatal and nonfatal cases. Among fatalities, antidiabetics (81.8%) and salicylates (60.3%) were the 2 drug classes that often were taken alone.

Opioids (RR, 5.20; 95% CI, 4.86-5.57) and barbiturates (RR, 4.29; 95% CI, 3.35-5.45) consistently had the highest unadjusted RRs in all periods. That pattern persisted in the regression-adjusted RRs shown in [Table 3](#zoi200041t3){ref-type="table"}. The risk of a suicide act resulting in death was highest if opioids were involved, with a best estimate that death was 5.18 (95% CI, 4.81-5.58) times more likely. Across sensitivity analyses, this estimate ranged from 3.99 to 6.86. As [Table 3](#zoi200041t3){ref-type="table"} shows, this estimate translates as 75% to 87% of the suicide deaths involving opioids would not have been fatal if opioids were not involved.

###### Relative Risks and Attributable Fractions Derived From Logistic Regressions

  Variable                                                          RR (95% CI)           Sensitivity analysis range, estimate from models 2, 3, and 5[^b^](#zoi200041t3n2){ref-type="table-fn"}   
  ----------------------------------------------------------------- --------------------- -------------------------------------------------------------------------------------------------------- ---------------
  4-Aminophenol derivative                                          0.94 (0.82 to 1.09)   0.86 (0.71 to 1.03)                                                                                      0.63 to 1.06
  Alcohol                                                           2.04 (1.84 to 2.26)   1.50 (1.32 to 1.72)                                                                                      2.00 to 2.49
  Antiallergic/antiemetic                                           3.94 (3.48 to 4.45)   1.17 (0.98 to 1.39)                                                                                      2.69 to 4.72
  Antidepressant                                                    3.22 (2.95 to 3.52)   2.75 (2.48 to 30.5)                                                                                      1.95 to 3.82
  Antidiabetic                                                      2.57 (1.94 to 3.41)   NA                                                                                                       2.13 to 3.06
  Antiepileptic                                                     1.20 (1.05 to 1.39)   0.91 (0.75 to 1.10)                                                                                      0.83 to 1.43
  Antiparkinsonian                                                  0.67 (0.53 to 0.87)   NA                                                                                                       0.64 to 0.78
  Barbiturate                                                       4.29 (3.35 to 5.45)   NA                                                                                                       4.26 to 4.64
  Benzodiazepine                                                    0.71 (0.66 to 0.78)   0.44 (0.39 to 0.49)                                                                                      0.43 to 0.85
  Cocaine                                                           1.30 (1.08 to 1.58)   1.10 (0.85 to 1.40)                                                                                      1.09 to 1.64
  Hallucinogen                                                      0.20 (0.11 to 0.35)   NA                                                                                                       0.18 to 0.23
  Muscle relaxant                                                   0.04 (0.01 to 0.14)   NA                                                                                                       0.05 to 0.05
  Opioid                                                            5.20 (4.86 to 5.57)   5.18 (4.81 to 5.58)                                                                                      3.99 to 6.86
  Other analgesic                                                   0.47 (0.18 to 1.16)   NA                                                                                                       0.42 to 0.60
  Other antipsychotic                                               1.50 (1.31 to 1.73)   1.24 (0.85 to 1.40)                                                                                      0.99 to 1.74
  Other NSAID                                                       0.24 (0.16 to 0.35)   NA                                                                                                       0.16 to 0.26
  Psychostimulant                                                   1.44 (1.17 to 1.77)   1.26 (0.98 to 1.63)                                                                                      1.22 to 1.72
  Salicylate                                                        1.59 (1.20 to 2.10)   NA                                                                                                       1.16 to 1.85
  Other named drug class                                            1.18 (1.07 to 3.18)   NA                                                                                                       1.05 to 1.42
  Unknown drug only                                                 2.92 (2.64 to 3.20)   NA                                                                                                       1.90 to 4.28
  Attributable fraction[^c^](#zoi200041t3n3){ref-type="table-fn"}                                                                                                                                  
  4-Aminophenol derivative                                          NA                    NA                                                                                                       0.06 to 2.72
  Alcohol                                                           0.51 (0.46 to 0.56)   0.34 (0.24 to 0.42)                                                                                      0.50 to 0.61
  Antiallergic/antiemetic                                           0.75 (0.71 to 0.78)   0.14 (−0.02 to 0.28)                                                                                     0.63 to 0.80
  Antidepressant                                                    0.69 (0.66 to 0.72)   0.64 (0.60 to 0.67)                                                                                      0.49 to 0.75
  Antidiabetic                                                      0.61 (0.48 to 0.71)   NA                                                                                                       0.53 to 0.69
  Antiepileptic                                                     0.17 (0.05 to 0.28)   −0.10 (−0.33 to 0.09)                                                                                    NA
  Antiparkinsonism                                                  NA                    NA                                                                                                       NA
  Barbiturate                                                       0.77 (0.70 to 0.82)   NA                                                                                                       0.77 to 0.80
  Benzodiazepine                                                    NA                    NA                                                                                                       NA
  Cocaine                                                           0.23 (0.07 to 0.37)   0.09 (−0.17 to 0.28)                                                                                     0.08 to 0.40
  Hallucinogen                                                      NA                    NA                                                                                                       NA
  Muscle relaxant                                                   NA                    NA                                                                                                       NA
  Opioid                                                            0.81 (0.79 to 0.82)   0.81 (0.79 to 0.82)                                                                                      0.75 to 0.87
  Other analgesic                                                   NA                    NA                                                                                                       NA
  Other antipsychotic                                               0.33 (0.24 to 0.42)   0.20 (0.05 to 0.32)                                                                                      0.44 to 101.0
  Other NSAID                                                       NA                    NA                                                                                                       NA
  Psychostimulant                                                   0.30 (0.14 to 0.44)   0.21 (−0.02 to 0.39)                                                                                     0.18 to 0.43
  Salicylate                                                        0.37 (0.16 to 0.52)   NA                                                                                                       0.13 to 0.47
  Other named drug class                                            0.15 (0.06 to 0.69)   NA                                                                                                       0.05 to 0.30
  Unknown drug only                                                 0.66 (0.62 to 0.69)   NA                                                                                                       0.47 to 0.78

Abbreviations: NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug; RR, relative risk.

A cross-product model was not run if fewer than 100 fatalities were in the drug class. No cross-product model was run on unknown drugs.

Odds ratios and associated 95% CIs underlying the RRs in the sensitivity analyses appear in eTable 2 and eTable 5 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"}.

Calculated if the RR exceeded 1.00.

Relative to the fatality risk for all other drugs combined, antiallergics or antiemetics (RR, 3.94; 95% CI, 3.48-4.45), antidepressants (RR, 3.22; 95% CI, 2.95-3.52), and alcohol (RR, 2.04; 95% CI, 1.84-2.26) had high RRs in the linear model (model 1), but their association was attenuated in a cross-product model (model 4) that accounted for the presence of other drugs. Too few cases involved barbiturates to test whether its high RR would attenuate. The RR for antidiabetics almost certainly would not attenuate because more than 80% of those deaths involved no other drugs. Besides opioids (81%), the attributable fraction of deaths involving another drug only exceeded 0.5 for barbiturates (77%), antidepressants (64%), and antidiabetics (61%). Among alcohol-involved deaths, 34% were alcohol attributable.

eTable 2 and eTable 5 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} provide the full regression models that produced the results in the sensitivity analysis column in [Table 3](#zoi200041t3){ref-type="table"}. eTable 6 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} displays the regressions underlying the interaction models.

[Table 4](#zoi200041t4){ref-type="table"} as well as eTable 7 and eTable 8 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"} compare drug suicide patterns of youths and adults. After controlling for drugs chosen, lethality was lower for youths than adults. The drug mixes chosen by youths and adults contrasted markedly. Youth poisoning suicide acts were more likely to include nonopioid pain relievers (eg, acetaminophen, aspirin, or ibuprofen), antidepressants, and antiallergic or antiemetic drugs. In contrast, attempts in adults were more likely to include alcohol, benzodiazepines, cocaine, opioids, and drugs to treat chronic conditions (eg, epilepsy, Parkinson disease). The adult regression yielded almost identical odds ratios by drug to the all-age model. The youth regression was hampered by sample size. With a broad 95% CI, the RRs of death for opioids (8.36 \[95% CI, 5.36-13.00\] vs 5.07 \[95% CI, 4.73-5.42\]) and barbiturates (9.43 \[95% CI, 1.26-62.26\] vs 4.22 \[95% CI, 3.31-5.36\]) were larger for youths than adults. Conversely, alcohol involvement only was associated with increased risk among adults (RR, 2.06 \[95% CI, 1.86-2.29\] vs 0.25 \[95% CI, 0.03-1.85\]).

###### Youth and Adult Toxin Distributions, RRs, and Attributable Fractions for 2011-2012 State Data

  Drug                       Distribution, No. (%)   RR (95% CI)                                                                                                                        
  -------------------------- ----------------------- --------------- ----------- ------------- ------------- --------------- ------------------- ------------------ ------------------- ------------------
  4-Aminophenol derivative   7658 (1.6)              54 834 (17.4)   6 (4.9)     272 (5.5)     3182 (23.4)   11 893 (11.4)   0.27 (0.08-0.51)    0.59 (0.52-0.66)   0.43 (0.19-1.01)    0.97 (0.84-1.12)
  Alcohol                    1723 (3.6)              17 751 (8.9)    1 (0.8)     549 (11.1)    576 (3.5)     8044 (7.7)      0.22 (0.00-0.73)    1.52 (1.39-1.66)   0.25 (0.03-1.85)    2.06 (1.86-2.29)
  Antiallergic/antiemetic    2906 (6.1)              6911 (3.5)      11 (8.9)    362 (7.3)     1246 (7.6)    3968 (3.8)      1.51 (0.71-2.55)    2.18 (1.96-2.41)   2.13 (1.07-4.27)    3.98 (3.51-4.51)
  Antidepressant             5841 (12.3)             21 730 (10.9)   17 (13.8)   834 (16.8)    2670 (16.4)   13 893 (13.3)   1.15 (0.61-1.83)    1.64 (1.53-1.76)   2.43 (1.38-4.27)    3.21 (2.94-3.51)
  Antidiabetic               361 (0.8)               2856 (1.4)      1 (0.8)     54 (1.1)      218 (1.3)     2100 (2.0)      1.07 (0.00-3.60)    0.75 (0.56-0.95)   2.78 (0.37-19.95)   2.55 (1.92-3.37)
  Antiepileptic              1156 (2.4)              10 507 (5.3)    2 (1.6)     280 (5.6)     473 (2.9)     6329 (6.1)      0.66 (0.00-1.73)    1.07 (0.95-1.20)   0.77 (0.19-3.14)    1.21 (1.05-1.40)
  Antiparkinsonian           419 (0.9)               4987 (2.5)      1 (0.8)     80 (1.6)      173 (1.1)     2705 (2.6)      0.92 (0.00-3.13)    0.64 (0.50-0.78)   0.61 (0.08-4.47)    0.69 (0.54-0.87)
  Barbiturate                101 (0.2)               1447 (0.7)      1 (0.8)     94 (1.9)      65 (0.4)      1081 (1.0)      3.86 (0.00-13.07)   2.63 (2.12-3.16)   9.43 (1.26-62.26)   4.22 (3.31-5.36)
  Benzodiazepine             4565 (9.6)              50 896 (25.6)   10 (8.8)    798 (16.1)    1951 (12.0)   32 336 (31.0)   0.83 (0.34-1.45)    0.56 (0.52-0.60)   0.71 (0.36-1.40)    0.72 (0.66-0.78)
  Cocaine                    381 (0.7)               9320 (4.7)      0           130 (2.6)     163 (1.0)     6833 (6.5)      NA                  0.55 (0.45-0.64)   NA                  1.33 (1.10-1.60)
  Hallucinogen               1489 (3.1)              2863 (1.4)      1 (0.8)     12 (0.2)      390 (2.4)     1525 (1.5)      0.25 (0.00-0.87)    0.55 (0.45-0.64)   0.18 (0.03-1.33)    0.20 (0.11-0.37)
  Muscle relaxant            434 (0.9)               3555 (1.8)      0           3 (0.1)       227 (1.4)     2480 (2.4)      NA                  0.03 (0.00-0.08)   NA                  0.04 (0.01-0.14)
  Opioid                     3318 (7.0)              34 548 (17.4)   45 (36.6)   1936 (39.0)   1248 (7.7)    18 496 (17.7)   7.70 (5.23-10.95)   3.04 (2.88-3.21)   8.36 (5.36-13.00)   5.07 (4.73-5.42)
  Other analgesic            3203 (0.9)              13 957 (7.0)    6 (4.9)     276 (5.6)     1522 (9.3)    9294 (8.9)      NA                  0.36 (0.07-0.71)   NA                  0.49 (0.19-1.21)
  Other antipsychotic        1823 (7.0)              4712 (2.4)      6 (4.9)     110 (2.2)     669 (4.1)     2763 (2.6)      0.71 (0.22-1.39)    0.78 (0.69-0.88)   1.11 (0.47-2.61)    1.51 (1.31-1.74)
  Other NSAID                5593 (0.5)              6340 (3.2)      0           26 (0.5)      1791 (11.0)   3003 (2.9)      NA                  0.16 (0.10-0.22)   NA                  0.27 (0.18-0.40)
  Psychostimulant            1723 (6.7)              14 979 (7.5)    1 (0.8)     549 (11.1)    576 (3.5)     8044 (7.7)      1.29 (0.38-2.49)    0.93 (0.76-1.11)   1.31 (0.55-3.09)    1.43 (1.16-1.77)
  Salicylate                 2040 (3.8)              3189 (1.6)      4 (3.3)     54 (1.1)      1031 (6.3)    2204 (2.1)      0.75 (0.17-1.61)    0.67 (0.50-0.86)   1.61 (0.57-4.47)    1.58 (1.17-2.10)
  Other named drug class     8246 (17.3)             30 642 (15.4)   17 (13.8)   529 (10.7)    3471 (21.3)   18 950 (18.2)   0.77 (0.42-1.21)    0.65 (0.60-0.71)   1.06 (0.62-1.84)    1.17 (1.06-1.30)
  Unknown drug only          4843 (10.2)             14 423 (7.3)    11 (8.9)    693 (14.0)    639 (3.9)     2833 (2.8)      0.87 (0.43-1.47)    2.07 (1.91-2.24)   0.98 (0.48-1.97)    2.98 (2.71-3.28)

Abbreviations: NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug; RR, relative risk.

The 2012 patterns for the 11 states and the nation shown in [Table 2](#zoi200041t2){ref-type="table"} were similar. The 2012 and 2016 national data were similar as well, except opioid-involved fatalities increased from 33.3% to 47.8%. Probing the data revealed that this resulted exclusively from deaths involving fentanyl and other synthetic opioids more than tripling from 516 to 1798 deaths.

A few drugs frequently involved in suicide acts are identifiable in *ICD-10* but not *ICD-9-CM*. Relative risks for those drugs, based on 2016 data unadjusted for demographic characteristics and comorbidities, appear in eTable 9 in the [Supplement](#note-ZOI200041-1-s){ref-type="supplementary-material"}. The attributable fraction of involved deaths for calcium channel blockers was high at 55% (RR, 2.24; 95% CI, 1.89-2.61).

Discussion {#H1-4-ZOI200041}
==========

This analysis found that including opioids or barbiturates in a suicidal drug mix increased the risk that a suicide attempt would prove lethal. The increase in lethality of suicidal opioid overdoses from 2012 to 2016 paralleled the rise in unintentional overdose deaths, which resulted from the spread of nonpharmaceutical fentanyl and analogues.^[@zoi200041r31]^

Adults were much more likely than youths to include highly lethal drugs in their suicidal mix. The descriptive data suggest that youths took whatever was at hand, including nonopioid analgesics, allergy medications, or anything easily accessible.^[@zoi200041r32]^ This finding emphasizes the importance of locking up drugs prescribed to any family member if they can be lethal in overdose.^[@zoi200041r33]^ Parents of children with depression or who have multiple risks probably would be wise to compile a list of all their family's medications and ask their pharmacist to check for drugs that are likely to be lethal if combined in an overdose. Disposing of leftover drugs may also help prevent a fatal suicide attempt.^[@zoi200041r34]^

Limiting access to lethal means is a proven way to prevent suicides.^[@zoi200041r35],[@zoi200041r36],[@zoi200041r37],[@zoi200041r38]^ Smaller pack size and blister packaging proved protective against suicide by paracetamol.^[@zoi200041r11],[@zoi200041r39]^ To reduce suicide risk, we recommend blister packing all opioids and other potentially lethal drugs.^[@zoi200041r40],[@zoi200041r41]^ Suicidal acts often are impulsive, and once underway, the individual is impatient.^[@zoi200041r42]^ Youths, in particular, are likely to simply choose a different bottle rather than patiently empty blister packs.

Adults used more considered drug mixes than youths. Their mixes increased lethality. It is unclear why adults had higher mortality rates than youths when they included alcohol in their mix. Possibly they took more drugs that interacted adversely with alcohol. Conversely, alcohol use disorder is a known risk factor for suicide.^[@zoi200041r43],[@zoi200041r44],[@zoi200041r45]^ Therefore, alcohol involvement among adults might serve as a marker for alcohol use disorders that focused attempters on more lethal drug mixes. Antidepressant involvement might provide a similar signal.

The opioid-involved suicide rate more than doubled from 1999 and 2009, then stabilized.^[@zoi200041r46]^ In reporting the death toll from the opioid epidemic, analysts routinely include these opioid-involved suicides.^[@zoi200041r47],[@zoi200041r48],[@zoi200041r49]^ Our analysis confirms the wisdom of including them.^[@zoi200041r47]^ It suggests that 75% to 87% of these deaths would not have occurred if the decedent had lacked access to opioids. Suicide acts often are impulsive and use readily accessible, often previously ideated means, so those who intentionally overdosed on opioids would be likely to try a drug overdose even if opioids were not readily available.^[@zoi200041r35],[@zoi200041r36]^ However, without opioids in the mix, it appears that they probably would survive.

Reducing opioid involvement could save lives beyond the short term. A meta-analysis of predominantly drug poisoning cases found only 2.1% of suicide survivors died by suicide in the following 2 years.^[@zoi200041r50]^ Indeed, means matter.

Limitations {#H2-2-ZOI200041}
-----------

This study has some limitations. Our analysis was hampered by coding deficiencies in mortality and hospital data. First, only a subset of drug self-intoxication cases coded as undetermined intent were suicidal.^[@zoi200041r47]^ Of the fatalities in [Table 1](#zoi200041t1){ref-type="table"}, 27.6% were of undetermined intent, whereas none of the drugs involved were identified in 14.6% of cases. For nonfatal cases in [Table 1](#zoi200041t1){ref-type="table"}, these percentages were 27.1% and 8.5%, respectively. Furthermore, 30% of death certifiers would not have tested for alcohol in drug poisonings, so our alcohol-attributable fraction is probably an underestimate.^[@zoi200041r51]^ Our regression-based estimates of the attributable fractions omitting cases with undetermined intent and unknown drug were similar to estimates including them. Second, we unavoidably omitted fatal and nonfatal suicide acts that were deliberately miscoded as unintentional to avoid stigma or insurance problems. Third, we unavoidably omitted suicide acts among the 8.3% of *ICD-9-CM* drug poisoning cases that lacked external cause codes. Although poisoning intent cannot be omitted in *ICD-10-CM*, coders are encouraged to code as unintentional rather than undetermined. The net effect of these omissions and overinclusions is unclear. Nevertheless, some readers may prefer to view the results omitting undetermined intent (model 3) as primary.

Differences in drug coding between *ICD* editions and sparse counts also limited our analysis. The *ICD-9-CM*, which underpinned our regression-adjusted estimates, lumped other drugs with cannabis, β-blockers, and calcium channel blockers. We had too few cases involving most drugs to use cross-product regressions that adjusted for drug interactions. Consequently, we could only provide 2016 unadjusted RR estimates for those drugs. For some other drugs, we saw dramatic declines in RR from unadjusted or linear regression to cross-product regression estimates. Regressions using pooled 2016 and 2017 state census data would improve our estimates.

Our data also lack recency. Comparing 2012 and 2016 data, however, suggested that the risk pattern has been stable for all drugs except opioids.

Our regression results may not be nationally representative. We used 2011-2012 data from a convenience sample of states that made affordable hospital discharge censuses available. Although we lack data from the Appalachian states that were hard hit by the opioid epidemic, we have state data from the coasts and heartland, as well as populous and sparsely populated states. Furthermore, the data sets lacked important demographic explanators, including race, ethnicity, and income. Our concerns about representativeness are softened by the consistency of the RRs in the 2011-2012 data before regression adjustment with the national RRs for 2012.

Conclusions {#H1-5-ZOI200041}
===========

The suicide prevention concept of "means matter" extends to drug class within poisoning suicides. This study appears to reemphasize the need to control access to drug classes that increase the risk of dying of a suicidal overdose. This study suggests that lethal drug access is particularly an issue for youths because they rarely take a targeted set of drugs, seemingly opting for whatever is accessible.
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**eTable 1.** Drug Codes for Poisonings of Suicidal and Undetermined Intent, by Coding System

**eTable 2.** Regression Model for 2011-2012 Data Including All Suicide Mechanisms (n = 415 595)

**eTable 3.** Case Fatality Rates (CFR), Case Counts of Suicidal Intent-Only Drug Poisoning Overdoses, and Unweighted Case Counts for 2012 and 2016 NIS/NEDS Data

**eTable 4.** Percent of Cases in the 2011-2012 Overdoses Where a Given Drug Class Was the Only Drug Class Identified

**eTable 5.** Complete Regression Output for Model 1 and Sensitivity Analyses for Models Excluding Unknown Drugs and Excluding Cases of Undetermined Intent

**eTable 6.** Regression Models and Coefficients for Drug Interactions Used to Generate Combined Odds Ratios

**eTable 7.** Drug Frequencies by Setting for Adults (n = 198 410) and Youths (n = 47 625) in the 2011-2012 Data Used to Generate the Percentages and Regression in [Table 4](#zoi200041t4){ref-type="table"}

**eTable 8.** Regression Models and Odds Ratios for the Population Divided Into Youth (Age 6-20) and Adult (Age 21 and Older)
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